Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tardyferon
- Development stage
- Phase 3
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tardyferon is an oral iron supplementation medication developed by Pierre Fabre Médicament for the treatment and prevention of iron deficiency anemia. The active ingredient is ferrous sulfate, which is provided in a prolonged-release (sustained-release) formulation to ensure gradual iron release in the gastrointestinal tract, thereby improving gastrointestinal tolerability and optimizing absorption. It is primarily indicated for iron deficiency states, including those associated with pregnancy, lactation, and inadequate dietary intake or impaired absorption. By providing elemental iron, Tardyferon facilitates the synthesis of hemoglobin, which is essential for oxygen transport in the blood.
- Brand names
- Tardyferon
- Other names
- ferrous sulfateferrous sulphateferrous sulfate heptahydrate
Beyond the preview
Go deeper on Tardyferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tardyferon.